Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Trabedersen,Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Funding
Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID
Details : OT-101 (trabedersen) has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer. It has pediatric designation for a rare form of pediatric brain cancer known as DIPG.
Brand Name : OT-101
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 12, 2022
Lead Product(s) : Trabedersen,Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Artemisinin,Curcumin,Boswellia Serrata
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : MGC Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
HempStreet Announces Partnership with MGC Pharma to Revolutionise Global Phytomedicine Sector
Details : Through this partnership, and through HempStreet’s extensive distribution reach and key institutional partnerships, Indian patients will now have access to these medicines, starting with CimetrA (Artemisinin), which had an immediate need.
Brand Name : CimetrA
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 07, 2022
Lead Product(s) : Artemisinin,Curcumin,Boswellia Serrata
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : MGC Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Artemisinin,Curcumin,Frankincense
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : MGC Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study includes 150 adult patients with a confirmed SARS-CoV-2 infection, at least 4 weeks of long-COVID symptoms, and a Post Covid Functional Score (PCFS) between one and four. ArtemiC Support is administered orally, in a dosage of 5 drops three time...
Brand Name : ArtemiC
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 21, 2021
Lead Product(s) : Artemisinin,Curcumin,Frankincense
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : MGC Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pulmoheal™/ Artiveda™ Is Clinically Active Against Mild and Moderate Covid-19
Details : PulmoHeal/ ArtiVeda has proven active against COVID-19 in ARTI-19 clinical trial (A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects w...
Brand Name : PulmoHeal
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 24, 2021
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Manus Bio Awarded Additional Funding To Support Its Artemisinin Development Program
Details : Manus Bio has received a third funding award from the Bill & Melinda Gates Foundation to accelerate the development of a scalable and cost-effective production method for artemisinin, a key therapeutic for treating malaria.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 01, 2021
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Trabedersen,Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Oncotelic
Deal Size : Not Applicable
Deal Type : Not Applicable
Mateon’s Update on C001 - Global Study for Ot-101 Against Covid-19
Details : Mateon has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients which allows for the continuing expansion to the targeted 18 patients in part 1 and 18 patients in part 2. OT-101 is an antisense against the host TGF-β protein.
Brand Name : OT-101
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 08, 2021
Lead Product(s) : Trabedersen,Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Oncotelic
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Artemisinin,Curcumin,Boswellia Serrata
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Malta Enerprises
Deal Size : $3.7 million
Deal Type : Funding
MGC Pharmaceuticals Receives Cash Grant to Help Establish ArtemiCTM Productioninn Malta
Details : The Malta facility will create a European manufacturing hub for ArtemiCTM with the ability to scale production to meet expected growing demand following positive clinical trial results.
Brand Name : ArtemiC
Molecule Type : Small molecule
Upfront Cash : $3.7 million
December 22, 2020
Lead Product(s) : Artemisinin,Curcumin,Boswellia Serrata
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Malta Enerprises
Deal Size : $3.7 million
Deal Type : Funding
Lead Product(s) : Artemisinin,Curcumin,Frankincense
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MGC Pharmaceuticals Provides ArtemiCTM Phase II Clinical Trial Results Update
Details : Interim Results reported to date demonstrate ArtemiCTM has met all primary end points for safety and efficacy, and FDA primary endpoint of sustained clinical recovery of COVID-19 patients.
Brand Name : ArtemiC
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 07, 2020
Lead Product(s) : Artemisinin,Curcumin,Frankincense
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Artemisinin,Curcumin,Frankincense
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The trial is assessing the safety and efficacy of the natural anti-inflammatory formulation ArtemiCTM, a natural supplement formula based on Artemisinin and Curcumin (along with supporting ingredients Vitamin C and Boswellia serrata) on COVID-19 Patients...
Brand Name : ArtemiC
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 28, 2020
Lead Product(s) : Artemisinin,Curcumin,Frankincense
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Mateon Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients. In-vitro, the medical grade version of the supplement has proven potency and safety similar to Remdesivir with an EC50 = 0.45 ug/ml and S...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 20, 2020
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Mateon Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?